Adjuvant Immune Checkpoint Inhibition in Muscle-invasive Bladder Cancer: Is It Ready for Prime Time?

Adi Kartolo; Wassim Kassouf; Francisco E Vera-Badillo

doi:10.1016/j.eururo.2021.07.019

Adjuvant Immune Checkpoint Inhibition in Muscle-invasive Bladder Cancer: Is It Ready for Prime Time?

Eur Urol. 2021 Dec;80(6):679-681. doi: 10.1016/j.eururo.2021.07.019. Epub 2021 Aug 6.

Authors

Adi Kartolo¹, Wassim Kassouf², Francisco E Vera-Badillo³

Affiliations

¹ Division of Medical Oncology, Department of Oncology, Queen's University, Kingston, Canada.
² Division of Urology, Department of Surgery, McGill University Health Center, Montreal, Canada.
³ Division of Medical Oncology, Department of Oncology, Queen's University, Kingston, Canada. Electronic address: francisco.verabadillo@kingstonhsc.ca.

PMID: 34366212
DOI: 10.1016/j.eururo.2021.07.019

Abstract

We discuss results from the Checkmate-274 and IMvigor010 trials on adjuvant immune checkpoint inhibitor (ICI) therapy in muscle-invasive bladder cancer (MIBC) with or without neoadjuvant chemotherapy (NAC), and conclude that adjuvant ICI (nivolumab but not atezolizumab) should be considered for patients with resected high-risk MIBC, especially for those who have received NAC.

Publication types

Editorial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Chemotherapy, Adjuvant
Cystectomy
Female
Humans
Immune Checkpoint Inhibitors* / adverse effects
Male
Muscles
Neoadjuvant Therapy
Neoplasm Invasiveness
Urinary Bladder Neoplasms* / surgery

Substances

Immune Checkpoint Inhibitors